Latest News

While we enjoy watching the progress our portfolio companies make, we appreciate this does not come easily and requires large measures of expertise, intuition, ingenuity and perseverance. This understanding increases our satisfaction in bringing you news of their accomplishments.

Use the filters above to refine results
10th May 2022

Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium

3rd May 2022

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

29th April 2022

HilleVax announces pricing of upsized Initial Public Offering

13th April 2022

GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn

12th April 2022

Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D., as Chairman of its Board of Directors

11th April 2022

We are delighted to announce that Abingworth LLP will become part of The Carlyle Group

11th April 2022

Nouscom Announces New Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors

4th April 2022

Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults

4th April 2022

Venatorx Pharmaceuticals Raises Series C Financing Led by the AMR Action Fund

29th March 2022

Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering

10th March 2022

Venatorx Pharmaceuticals Announces Positive Results for Phase 3 Clinical Trial (CERTAIN-1) of Cefepime-Taniborbactam for Treatment of cUTI

28th February 2022

Jasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive Officer

10th February 2022

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

9th February 2022

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)

25th January 2022

Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis

21st January 2022

Abingworth notes the passing of David Leathers, a former Director and Special Partner

18th January 2022

Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis

13th January 2022

Scorpion Therapeutics Enters Agreement with AstraZeneca to Discover, Develop and Commercialize Novel Cancer Treatments Against ‘Undruggable’ Targets

10th January 2022

Second Abingworth gamma delta T cell company, Adaptate Biotherapeutics, to be acquired by Takeda

6th January 2022

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease

5th January 2022

SPRUCE BIOSCIENCES APPOINTS JAVIER SZWARCBERG, M.D., MPH AS CHIEF EXECUTIVE OFFICER